相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Regulation and function of pyruvate kinase M2 in cancer
Weiwei Yang et al.
CANCER LETTERS (2013)
Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPO-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide
Niki Karachaliou et al.
PLOS ONE (2013)
Modulation of Glucose Metabolism by CD44 Contributes to Antioxidant Status and Drug Resistance in Cancer Cells
Mayumi Tamada et al.
CANCER RESEARCH (2012)
PKM2: A gatekeeper between growth and survival
Isaac Harris et al.
CELL RESEARCH (2012)
Pyruvate Kinase M2: Multiple Faces for Conferring Benefits on Cancer Cells
Mayumi Tamada et al.
CLINICAL CANCER RESEARCH (2012)
Pyruvate Kinase M2 Regulates Gene Transcription by Acting as a Protein Kinase
Xueliang Gao et al.
MOLECULAR CELL (2012)
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect
Weiwei Yang et al.
NATURE CELL BIOLOGY (2012)
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis
Dimitrios Anastasiou et al.
NATURE CHEMICAL BIOLOGY (2012)
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment
Sophie Postel-Vinay et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Emerging roles of PKM2 in cell metabolism and cancer progression
Weibo Luo et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2012)
CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc- and Thereby Promotes Tumor Growth
Takatsugu Ishimoto et al.
CANCER CELL (2011)
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
Weibo Luo et al.
CELL (2011)
Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells
Sybille Mazurek
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2011)
Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model
Wenhao Guo et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Acetylation Targets the M2 Isoform of Pyruvate Kinase for Degradation through Chaperone-Mediated Autophagy and Promotes Tumor Growth
Lei Lv et al.
MOLECULAR CELL (2011)
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
Weiwei Yang et al.
NATURE (2011)
Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients
Zacharenia Saridaki et al.
PLOS ONE (2011)
Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses
Dimitrios Anastasiou et al.
SCIENCE (2011)
HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer
Charles J. David et al.
NATURE (2010)
The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism
Cynthia V. Clower et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes
Arnold J. Levine et al.
SCIENCE (2010)
Tumoral Expression of TXR1 and TSP1 Predicts Overall Survival of Patients with Lung Adenocarcinoma Treated with First-line Docetaxel-Gemcitabine Regimen
Chara Papadaki et al.
CLINICAL CANCER RESEARCH (2009)
A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines
Eva Martinez-Balibrea et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth
Taro Hitosugi et al.
SCIENCE SIGNALING (2009)
Pyruvate kinase M2 is a phosphotyrosine-binding protein
Heather R. Christofk et al.
NATURE (2008)
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Heather R. Christofk et al.
NATURE (2008)
Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation
Paloma Bragado et al.
APOPTOSIS (2007)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death
Kyu Jin Choi et al.
CANCER RESEARCH (2007)
Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: A review
P Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pyruvate kinase type M2 and its role in tumor growth and spreading
S Mazurek et al.
SEMINARS IN CANCER BIOLOGY (2005)
Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial
V Georgoulias et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Malignant ascites increases the antioxidant ability of human ovarian (SKOV-3) and gastric adenocarcinoma (KATO-III) cells
WX Yang et al.
GYNECOLOGIC ONCOLOGY (2005)
Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines
BC Yoo et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Cisplatin: mode of cytotoxic action and molecular basis of resistance
ZH Siddik
ONCOGENE (2003)
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group
F Fossella et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
V Georgoulias et al.
LANCET (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells - Role of ERCC1-XPF
KV Ferry et al.
BIOCHEMICAL PHARMACOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
